Effects at a distance in α7 nAChR selective agonists: Benzylidene substitutions that regulate potency and efficacy

Neuropharmacology

Volumn 46, Issue 7, 2004, Pages 1023-1038

  Papke, Roger L ^a   Meyer, Edwin M ^a   Lavieri, Sophie ^b   Bollampally, Sirisha R ^a   Papke, Thaddeus A S ^a   Horenstein, Nicole A ^c   Itoh, Yoshitsugu ^d   Porter Papke, Julia K ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

^c Taiho Pharmaceuticals ^*  (United States)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

3 BA, 3 benzylidene anabaseine; Alzheimer's disease; BA, the class of benzylidene anabaseine compounds; GTS 21, 3 (2,4 dimethoxybenzylidene)anabaseine; Net charge analysis; Partial agonists; Voltage clamp; Xenopus oocytes

Indexed keywords

3 (4 HYDROXYBENZYLIDENE)ANABASEINE; 3 (4 TRIFLUOROMETHYLBENZYLIDENE)ANABASEINE; 3 (4' METHYLTHIOBENZYLIDENE)ANABASEINE; 3 BENZYLIDENE ANABASEINE; ALPHA3,BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR; ALPHA4,BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR; ANABASINE; BENZYLIDENE DERIVATIVE; BUNGAROTOXIN RECEPTOR; HYDROXYL GROUP; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZYLIDENE COMPOUNDS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; NICOTINIC AGONISTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 1842664292     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.01.005     Document Type: Article

References (34)

1. Beers W.H., Reich E. Structure and activity of acetylcholine. Nature. 228:1970;917-922.
2. Cohen B.N., Figl A., Quick M.W., Labarca C., Davidson N., Lester H.A. Regions of beta and beta 4 responsible for differences between the steady state dose-response relationships of the alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors. Journal of General Physiology. 105:1995;745-764.
3. 125I]α- bungarotoxin receptor subtypes. Molecular Pharmacology. 47:1995;164-171.
4. Figl A., Cohen B.N., Quick M.W., Davidson N., Lester H.A. Regions of β4β2 subunit chimeras that contribute to the agonist selectivity of neuronal nicotinic receptors. FEBS Letters. 308:1992;245-248.
5. Ji D., Dani J.A. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. Journal of Neurophysiology. 83:2000;2682-2690.
6. Ji D., Lape R., Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron. 31:2001;131-141.
7. Kem W.R., Mahnir V.M., Papke R.L., Lingle C.J. Anabaseine is a potent agonist upon muscle and neuronal alpha-bungarotoxin sensitive nicotinic receptors. Journal of Pharmacology and Experimental Therapeutics. 283:1997;979-992.
8. Le Novere N., Corringer P.J., Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. Journal of Neurobiology. 53:2002;447-456.
9. Li Y., King M.A., Meyer E.M. alpha7 nicotinic receptor-mediated protection against ethanol-induced oxidative stress and cytotoxicity in PC12 cells. Brain Research. 861:2000;165-167.
10. Lopez M.G., Montiel C., Herrero C.J., Garcia-Palomero E., Mayorgas I., Hernandez-Guijo J.M., Villarroya M., Olivares R., Gandia L., McIntosh J.M., Olivera B.M., Garcia A.G. Unmasking the functions of the chromaffin cell alpha7 nicotinic receptor by using short pulses of acetylcholine and selective blockers. Proceedings of the National Academy of Sciences USA. 95:1998;14184-14189.
11. Luetje C.W., Patrick J. Both α- and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. Journal of Neuroscience. 11:1991;837-845.
12. Mansvelder H.D., Keath J.R., McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron. 33:2002;905-919.
13. Marks M.J., Smith K.W., Collins A.C. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. Journal of Pharmacology and Experimental Therapeutics. 285:1998;377-386.
14. Martin E.J., Panikar K.S., King M.A., Deyrup M., Hunter B., Wang G., Meyer E. Cytoprotective actions ofdimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic cells. Drug Development Research. 31:1994;134-141.
15. Meyer E., Kuryatov A., Gerzanich V., Lindstrom J., Papke R.L. Analysis of 40H-GTS-21 selectivity and activity at human and rat α7 nicotinic receptors. Journal of Pharmacology and Experimental Therapeutics. 287:1998a;918-925.
16. Meyer E.M., King M.A., Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Research. 786:1998b;252-254.
17. Meyer E.M., Tay E.T., Zoltewicz J.A., Papke R.L., Meyers C., King M., Fiebre C.M.d. Neuroprotective and memory-related actions of novel α7 nicotinic agents with different mixed agonist/antagonist properties. Journal of Pharmacology and Experimental Therapeutics. 284:1998c;1026-1032.
18. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., Mack R., Loch J., Wu E. 3rd, Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulskis A., Zongrone J., Rosen A., Gordon J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. Journal of Medicinal Chemistry. 43:2000;4045-4050.
19. Papke R.L. Enhanced inhibition of a mutant neuronal nicotinic acetylcholine receptor by agonists: protection of function by (E)-N-methyl-4-(3-pyridinyl)-3-butene-1-amine (TC-2403). Journal of Pharmacology and Experimental Therapeutics. 301:2002;765-773.
20. Papke R.L., Bencherif M., Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neuroscience Letters. 213:1996;201-204.
21. Papke R.L., Duvoisin R.M., Heinemann S.F. The amino terminal half of the β subunit extracellular domain regulates the kinetics of the nicotinic antagonist, neuronal-bungarotoxin. Proceedings of the Royal Society London Series B. 252:1993;141-147.
22. Papke R.L., Papke J.K.P. Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. British Journal of Pharmacology. 137:2002;49-61.
23. Papke R.L., Thinschmidt J.S., Moulton B.A., Meyer E.M., Poirier A. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. British Journal of Pharmacology. 120:1997;429-438.
24. Papke R.L., Webster J.C., Lippiello P.M., Bencherif M., Francis M.M. The activation and inhibition of human nAChR by RJR-2403 indicate a selectivity for the α4β2 receptor subtype. Journal of Neurochemistry. 75:2000;204-216.
25. Parker M.J., Beck A., Luetje C.W. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity. Molecular Pharmacology. 54:1998;1132-1139.
26. Radcliffe K.A., Dani J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. Journal of Neuroscience. 18:1998;7075-7083.
27. Sharma G., Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. Journal of Neurobiology. 53:2002;524-534.
28. Shimohama S., Greenwald D.L., Shafron D.H., Akaike A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Research. 779:1998;359-363.
29. Uteshev V.V., Meyer E.M., Papke R.L. Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. Brain Research. 948:2002;33-46.
30. Uteshev V.V., Meyer E.M., Papke R.L. Regulation of neuronal function by choline and 4OH-GTS-21 through α7 nicotinic receptors. Journal of Neurophysiology. 89:2003;33-46.
31. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 421:2003;384-388.
32. Zhang J., Steinbach J.H. Cytisine binds with similar affinity to nicotinic alpha4beta2 receptors on the cell surface and in homogenates. Brain Research. 959:2003;98-102.
33. Zhou F.M., Liang Y., Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neuroscience. 4:2001;1224-1229.
34. Zwart R., Vijverberg H.P. Potentiation and inhibition of neuronal alpha4beta4 nicotinic acetylcholine receptors by choline. European Journal of Pharmacology. 393:2000;209-214.